Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC-sEV-001 in Ischemic Stroke
NCT07232563Phase 1Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exosomes derived from human umbilical cord blood mesenchymal stem cells in ischemic stroke, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Dose-Limiting Toxicity at Day 14. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
exosomes derived from human umbilical cord blood mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07232563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232563.